Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Storkus

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 27, 2001
Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cellsT K Hoffmann, N Meidenbauer, J Müller-Berghaus, et al.
Cancer Gene Therapy|March 17, 1999
Induction of tumor antigen-specific immunity using plasmid DNA immunization in miceT Tüting, A Gambotto, A DeLeo, et al.
The Journal of Experimental Medicine|January 1, 1996
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunityC M Celluzzi, J I Mayordomo, W J Storkus, et al.
Cancer Gene Therapy|April 29, 2006
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitroL Vujanovic, E Ranieri, A Gambotto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1993
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytesW J Storkus, H J Zeh, M J Maeurer, et al.
Annals of the New York Academy of Sciences|October 31, 1996
IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivoL Zitvogel, B Couderc, J I Mayordomo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 29, 1998
Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitroT Tjandrawan, D M Martin, M J Maeurer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 1999
Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cellsX Dong, B An, L Salvucci Kierstead, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2001
Human thymic epithelial cells inhibit IL-15- and IL-2-driven differentiation of NK cells from the early human thymic progenitorsP T Le, K L Adams, N Zaya, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 1999
Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human bloodW Herr, E Ranieri, A Gambotto, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 27, 2001
Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cellsT K Hoffmann, N Meidenbauer, J Müller-Berghaus, et al.
Cancer Gene Therapy|March 17, 1999
Induction of tumor antigen-specific immunity using plasmid DNA immunization in miceT Tüting, A Gambotto, A DeLeo, et al.
The Journal of Experimental Medicine|January 1, 1996
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunityC M Celluzzi, J I Mayordomo, W J Storkus, et al.
Cancer Gene Therapy|April 29, 2006
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitroL Vujanovic, E Ranieri, A Gambotto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1993
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytesW J Storkus, H J Zeh, M J Maeurer, et al.
Annals of the New York Academy of Sciences|October 31, 1996
IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivoL Zitvogel, B Couderc, J I Mayordomo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 29, 1998
Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitroT Tjandrawan, D M Martin, M J Maeurer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 1999
Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cellsX Dong, B An, L Salvucci Kierstead, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2001
Human thymic epithelial cells inhibit IL-15- and IL-2-driven differentiation of NK cells from the early human thymic progenitorsP T Le, K L Adams, N Zaya, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 1999
Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human bloodW Herr, E Ranieri, A Gambotto, et al.
Pageof 8